-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target

Benzinga·04/07/2025 11:34:41
Listen to the news
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and maintains $20 price target.